Dechra Pharmaceuticals trades in line with FY expectations
9th Jul 2020 08:08
(Sharecast News) - Veterinary pharmaceuticals group Dechra Pharmaceuticals said on Thursday that trading in the year ended 30 June was "robust" and in line with management expectations.
Read moreFriday broker round-up
5th Jun 2020 13:47
(Sharecast News) - Burberry: Goldman Sachs downgrades to sell with a target price of 1,490p.
Read moreDechra Pharmaceuticals raises £133.4m in placing
4th Jun 2020 07:51
(Sharecast News) - Dechra Pharmaceuticals has raised £133.4m in a placing to fund an acquisition and bolster its finances as it looks to weather any Covid-related disruption.
Read moreCompetition watchdog launches probe into Dechra's $135m Elanco deal
20th Apr 2020 11:57
(Sharecast News) - The Competition and Markets Authority has launched an investigation into Dechra Pharmaceuticals' $135m acquisition of Elanco Animal Health's Osurnia brand.
Read moreDechra Pharmaceuticals buys worldwide rights to Mirataz product portfolio
17th Mar 2020 08:46
(Sharecast News) - Veterinary medicines specialist Dechra Pharmaceuticals has agreed to acquire the worldwide rights to Kindred Biosciences' Mirataz product portfolio for $43m.
Read moreTuesday broker round-up
25th Feb 2020 13:15
(Sharecast News) - Redrow: Jefferies upgrades to buy with a target price of 981p.
Read moreDechra reiterates guidance despite supply chain issues
24th Feb 2020 08:05
(Sharecast News) - Veterinary products manufacturer Dechra Pharmaceuticals kept its full-year outlook unchanged on Monday despite warning that North American trading would remain challenging due to some persistent supply chain issues.
Read moreTuesday broker round-up
21st Jan 2020 12:47
(Sharecast News) - Ricardo: Berenberg upgrades to hold with a target price of 770p.
Read moreDechra Pharmaceuticals banking on rest of year after first half struggles
16th Jan 2020 09:07
(Sharecast News) - Dechra Pharmaceuticals updated the market on its trading for the half-year ended 31 December on Thursday, reporting that its outlook for the full year was in line with management expectations.
Read moreDechra Pharmaceuticals buys worldwide rights to Osurnia product portfolio
6th Jan 2020 08:13
(Sharecast News) - Veterinary drugs business Dechra Pharmaceuticals has acquired the worldwide rights to Osurnia's product portfolio from Elanco Animal Health for $135m, financed from existing cash and borrowing facilities.
Read moreDechra Pharmaceuticals appoints Paul Sandland as permanent CFO
30th Oct 2019 09:15
(Sharecast News) - Dechra Pharmaceuticals on Wednesday appointed Paul Sandland as an executive director and permanent chief financial officer with immediate effect.
Read moreFTSE 250 movers: Dunelm dives, CYBG climbs
10th Oct 2019 14:26
(Sharecast News) - London's FTSE 250 was down by 0.29% at 19,115.38 in afternoon trade on Thursday with Dunelm leading the index lower.
Read moreFTSE 250 movers: IG Group climbs, Dunelm drops
19th Sep 2019 15:04
(Sharecast News) - London's FTSE 250 was 0.15% higher at 20,083.88 in afternoon trade on Thursday, with IG Group leading the index higher.
Read moreDirector dealings: Dechra chairman and CEO raise stakes
18th Sep 2019 15:49
(Sharecast News) - Dechra Pharmaceuticals revealed on Wednesday that chief executive officer Ian Page had offloaded 200,000 ordinary shares in the FTSE 250-listed veterinary drugs outfit.
Read moreSunday share tip: Dechra Pharmaceuticals
15th Sep 2019 19:58
(Sharecast News) - Joanne Hart at the Mail on Sunday pointed out that with more people than ever owning pets, consumers were looking to spend more on the furry friends, benefiting companies like Dechra Pharmaceuticals, which makes and sells drugs for animals.
Read more